Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by bringon10baggeron Apr 03, 2020 2:48pm

199 Views

Post# 30876961

RE:RE:New Report from Echelon

Obviously you have not been a follower just someone looking for a quick buck.............educate yourself..........

MidasLetterGuy wrote: Pretty balsy to reiterate "Top Pick" and $1.40 price target just days before the stock could fall to $0.15c on failure to meet endpoint. I'm thinking they must be pretty damn sure of good results or they'll have extremely pissed off clients and rekt credibility. But then again, investment bank picks/analysis is wrong all the time.

Bullboard Posts

Invest wiser with BMO's InvestorLine Platform features